| Predictors of anti-VEGF-associated retinal pigment epithelial tear using FA and OCT analysis. | |
| | |
MedLine Citation:
|
PMID: 18628724 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: To identify fluorescein angiography and optical coherence tomography (OCT) predictors for retinal pigment epithelial (RPE) tear in eyes with pigment epithelium detachment (PED) associated with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor (VEGF) modulating therapy. DESIGN: Retrospective comparative case series. METHODS: In a single institutional center, 60 consecutive patients with PED and neovascular age-related macular degeneration treated with VEGF modulating therapy (either pegaptanib, bevacizumab, or ranibizumab) for more than a 27-month period were included in the study. Fluorescein angiography (FA) and OCT imaging was performed before and after anti-VEGF therapy. Formal statistical analysis comparing the tear group to the nontear group was performed to identify high-risk features for RPE tear. RESULTS: RPE tear rate for eyes with vascularized PED receiving anti-VEGF therapy was 17% (10/60). There were highly statistically significant differences in the median PED size on fluorescein angiography (greatest linear diameter) (3.2 mm versus 1.8 mm, respectively; P < 0.001) and in the median maximum PED height on OCT (394 mum versus 149 mum, respectively; P = 0.001) between the tear group and nontear group. There was also a significant difference in terms of the presence of subretinal fluid on OCT between the two groups (87.5% versus 39%, respectively; P = 0.019). CONCLUSION: Large PED basal diameter and vertical height are correlated with an increased risk of developing an RPE tear after anti-VEGF therapy. Patients with large vascularized PED by fluorescein angiography and/or OCT analysis should be alerted of the risk for vision loss due to RPE tear after anti-VEGF therapy. |
| | |
Authors:
|
Allen Chiang; Louis K Chang; Fei Yu; David Sarraf |
Related Documents
:
|
23549424 - Endovascular repair versus open repair of ruptured abdominal aortic aneurysms: a multic... 18207164 - Visual function in anterior ischemic optic neuropathy: effect of vision restoration the... 21672014 - Enzyme replacement therapy for mucopolysaccharidosis ii from 3 months of age: 3-year fo... 23555454 - Preoperative non-ambulatory status predicts poor outcome after below knee bypass surgery. 1538444 - Initial experience with combined interferon-alpha 2b and carbon dioxide laser for the t... 21801094 - A meta-analysis comparing long-term recurrences of toenail onychomycosis after successf... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Retina (Philadelphia, Pa.) Volume: 28 ISSN: 1539-2864 ISO Abbreviation: Retina (Philadelphia, Pa.) Publication Date: 2008 Oct |
Date Detail:
|
Created Date: 2009-05-12 Completed Date: 2009-06-25 Revised Date: 2013-05-27 |
Medline Journal Info:
|
Nlm Unique ID: 8309919 Medline TA: Retina Country: United States |
Other Details:
|
Languages: eng Pagination: 1265-9 Citation Subset: IM |
Affiliation:
|
Jules Stein Eye Institute, University of California-Los Angeles, 100 Stein Plaza, Los Angeles, CA 90095, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Antibodies, Monoclonal / adverse effects, therapeutic use Antibodies, Monoclonal, Humanized Aptamers, Nucleotide / adverse effects, therapeutic use Choroidal Neovascularization / drug therapy, etiology Female Fluorescein Angiography* Humans Macular Degeneration / complications Male Predictive Value of Tests Retinal Detachment / diagnosis*, etiology Retinal Perforations / chemically induced* Retinal Pigment Epithelium* / blood supply Retinal Vessels / pathology Retrospective Studies Risk Assessment / methods Tomography, Optical Coherence* Vascular Endothelial Growth Factor A / antagonists & inhibitors* |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Aptamers, Nucleotide; 0/Vascular Endothelial Growth Factor A; 0/pegaptanib; 0/ranibizumab; 2S9ZZM9Q9V/bevacizumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabeti...
Next Document: Preferred retinal locus in macular disease: characteristics and clinical implications.